Drugs News and Research

RSS

FDA approves Brintellix drug to treat depressive disorder in adults

The U.S. Food and Drug Administration today approved Brintellix (vortioxetine) to treat adults with major depressive disorder.

1 Oct 2013

Huntsman investigator receives $1.5M to focus on c-KIT gene's role in melanoma

The National Cancer Institute (NCI) has awarded Huntsman Cancer Institute investigator Matt VanBrocklin, Ph.D., more than $1.5 million over the next five years to continue studying the role of a gene called c-KIT in the origin and growth of melanoma, a devastating and sometimes deadly skin cancer.

1 Oct 2013

OptimEx study may show how to prevent and limit extent of heart failure through exercise

OptimEx, a new 3.5-year study funded by the European Union and coordinated by the Norwegian University of Science and Technology (NTNU), will look at whether exercise could be used both to prevent and treat a specific type of heart failure.

1 Oct 2013

GSK Sells Thrombosis Brands To Aspen For $1.13B

...

30 Sep 2013

Use of psychotropic prescription medications in very young children stabilizing

The use of psychotropic prescription medications to treat ADHD, mood disorders, anxiety and other mental health disorders in very young children appears to have leveled off.

30 Sep 2013

Women with recurrent ovarian cancer survive longer after treatment with cediranib

Women with ovarian cancer that has recurred after chemotherapy have survived for longer after treatment with a biological therapy called cediranib, according to new results to be presented today (Monday) at the 2013 European Cancer Congress.

30 Sep 2013

A*STAR, NSC and NTU to expand skin research in Singapore

Singapore is committing close to S$100 million to skin research, with the announcement of the Skin Research Institute of Singapore. A collaboration between the Agency for Science Technology and Research, National Skin Centre and Nanyang Technological University, the SRIS will harness the expertise of scientists, clinicians and engineers to foster and conduct high impact, inter-disciplinary skin research designed to translate into improved health outcomes and quality of life.

30 Sep 2013

Omeros' OMS824 gets FDA orphan drug designation for treatment of Huntington's disease

Omeros Corporation announced that OMS824, its phosphodiesterase 10 inhibitor, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of Huntington's disease.

30 Sep 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis.

30 Sep 2013

Innovative packaging design aids convergence in the pharmaceutical industry

PCI, a global supplier of pharmaceutical commercial packaging solutions and clinical trials services, announces the availability of a white paper detailing how it’s innovative packaging design aids convergence in the pharmaceutical industry.

30 Sep 2013

Biology of tumour more important than primary site, say researchers

Identifying the molecular profile of a tumour where the primary site is unknown is crucial to the choice of treatment, the 2013 European Cancer Congress, will hear on Monday.

30 Sep 2013

Discoveries pave way for use of new therapies for advanced thyroid cancer

For many years, patients with advanced thyroid cancer faced bleak prospects and no viable treatment options. But now, building on recent discoveries about the genetics and cell signaling pathways of thyroid tumors, researchers are developing exciting new weapons against the disease, using kinase inhibitors that target tumor cell division and blood vessels.

30 Sep 2013

Colorectal cancer in younger people appears to be more aggressive

Younger patients with colorectal cancer that has spread (metastasised) to other parts of the body represent a high-risk group that is less likely to respond to anti-cancer treatments.

29 Sep 2013

First Phase II study: Everolimus drug slows spread of advanced papillary kidney cancer

The first Phase II study to investigate the use of the anti-cancer drug, everolimus, for the initial treatment of advanced papillary kidney cancer has shown that it is successful in slowing or preventing the spread of the disease, according to research to be presented today (Sunday) at the 2013 European Cancer Congress.

29 Sep 2013

Biochemists discover promising vitamin D-based treatment that can halt MS

A diagnosis of multiple sclerosis is a hard lot. Patients typically get the diagnosis around age 30 after experiencing a series of neurological problems such as blurry vision, wobbly gait or a numb foot. From there, this neurodegenerative disease follows an unforgiving course.

29 Sep 2013

c-Fos oncogene cab be important target for understanding and treatment of cancer

The c-Fos oncogene has traditionally been linked to cellular activities related to cancer, such as cell division, differentiation-conversion from one cell type to another-or survival. Any alteration of these activities can set off the development of tumours, which has made c-Fos an important target for the understanding and treatment of cancer.

29 Sep 2013

Studies show evidence-guided molecular profiling improves treatment for hard-to-treat cancers

Caris Life Sciences announced today data from two studies presented at the 2013 European Cancer Congress, which demonstrate the potential of evidence-guided molecular profiling to immediately improve the treatment of patients with hard-to-treat cancers, including cancers of unknown primary (CUP) origins as well as rare tumors and cancers that have been refractory to treatment.

29 Sep 2013

New intravaginal ring delivers drug effectively, guards against HIV for 1 month

It's often said that the HIV/AIDS epidemic has a woman's face. The proportion of women infected with HIV has been on the rise for a decade; in sub-Saharan Africa, women constitute 60 percent of people living with disease. While preventative drugs exist, they have often proven ineffective, especially in light of financial and cultural barriers in developing nations.

28 Sep 2013

White paper addresses needs, challenges and solutions for improving mCRC treatment

The Angiogenesis Foundation released a white paper at the 2013 European Cancer Congress that addresses the needs, challenges, and proposed solutions for improving treatment of metastatic colorectal cancer, the third most common cancer among men and the second most common among women worldwide.

28 Sep 2013

FDA expands Hizentra administration options for people with primary immunodeficiency

CSL Behring announced today that the U.S. Food and Drug Administration has expanded the administration options for Hizentra, Immune Globulin Subcutaneous (Human), 20% Liquid, to include dosing once every two weeks (biweekly) for people diagnosed with primary immunodeficiency.

28 Sep 2013

Drugs News and Research

FDA approves Brintellix drug to treat depressive disorder in adults

Huntsman investigator receives $1.5M to focus on c-KIT gene's role in melanoma

OptimEx study may show how to prevent and limit extent of heart failure through exercise

GSK Sells Thrombosis Brands To Aspen For $1.13B

Use of psychotropic prescription medications in very young children stabilizing

Women with recurrent ovarian cancer survive longer after treatment with cediranib

A*STAR, NSC and NTU to expand skin research in Singapore

Omeros' OMS824 gets FDA orphan drug designation for treatment of Huntington's disease

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

Innovative packaging design aids convergence in the pharmaceutical industry

Biology of tumour more important than primary site, say researchers

Discoveries pave way for use of new therapies for advanced thyroid cancer

Colorectal cancer in younger people appears to be more aggressive

First Phase II study: Everolimus drug slows spread of advanced papillary kidney cancer

Biochemists discover promising vitamin D-based treatment that can halt MS

c-Fos oncogene cab be important target for understanding and treatment of cancer

Studies show evidence-guided molecular profiling improves treatment for hard-to-treat cancers

New intravaginal ring delivers drug effectively, guards against HIV for 1 month

White paper addresses needs, challenges and solutions for improving mCRC treatment

FDA expands Hizentra administration options for people with primary immunodeficiency

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News